Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGG492 in photosensitive epilepsy
NCT00784212Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2008
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of selurampanel in photosensitive epilepsy (PSE) (3 cohorts), sponsored by Novartis. Primary endpoint: Photoparoxysmal response. Started Oct 2008; status: completed.
02
Drugs
selurampanel
03
Conditions
photosensitive epilepsy (PSE)
Beyond the preview
Go deeper on NCT00784212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00784212.